These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 19184608

  • 1. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
    Kampman MT, Steffensen LH.
    Ir J Med Sci; 2009 Jun; 178(2):235-6; author reply 237-8. PubMed ID: 19184608
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
    Kornhuber ME, Zierz S.
    Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
    Tilbery CP, Moreira MA, Mendes MF, Lana-Peixoto MA.
    Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
    [Abstract] [Full Text] [Related]

  • 8. Disease modifying treatment in multiple sclerosis.
    Fuller GN, Bone I.
    J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Editorial: the pitfalls of combination therapy.
    Vermersch P.
    Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
    [No Abstract] [Full Text] [Related]

  • 11. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
    Oger J, Freedman M.
    Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Factors leading patients to discontinue multiple sclerosis therapies.
    Daugherty KK, Butler JS, Mattingly M, Ryan M.
    J Am Pharm Assoc (2003); 2005 Nov; 45(3):371-5. PubMed ID: 15991759
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
    Tremlett HL, Oger J.
    Neurology; 2003 Aug 26; 61(4):551-4. PubMed ID: 12939437
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP.
    Mult Scler; 2001 Dec 26; 7(6):349-53. PubMed ID: 11795454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.